BWC0977   Click here for help

GtoPdb Ligand ID: 12809

Compound class: Synthetic organic
Comment: BWC0977 is an oxazolidinone class antibacterial claimed in patent WO2018225097A1 [1]. It has broad-spectrum antibacterial activity and is a type II DNA topoisomerase inhibitor with similar activity against DNA gyrase and DNA topoisomerase 4.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 11
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 124.93
Molecular weight 468.44
XLogP -1.79
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1C(=O)C=CC2=C1C(=C(C=C2)F)CCNC[C@@H]3CN(C4=NC5=C(N=C4)OCC(=O)N5)C(=O)O3
Isomeric SMILES CN1C(=O)C=CC2=C1C(=C(C=C2)F)CCNC[C@@H]3CN(C4=CN=C5C(=N4)NC(=O)CO5)C(=O)O3
InChI InChI=1S/C22H21FN6O5/c1-28-18(31)5-3-12-2-4-15(23)14(19(12)28)6-7-24-8-13-10-29(22(32)34-13)16-9-25-21-20(26-16)27-17(30)11-33-21/h2-5,9,13,24H,6-8,10-11H2,1H3,(H,26,27,30)/t13-/m1/s1
InChI Key MKICNOUBIXXGPQ-CYBMUJFWSA-N
No information available.
Summary of Clinical Use Click here for help
BWC0977 has advanced to first-in-human Phase 1 clinical evaluation (NCT05088421: recruitment complete, July 2023). It is being developed by Bugworks Research Inc., in partnership with the Global Antibiotic Research and Development Partnership (GARDP) and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), as an intravenous and oral treatment for a broad spectrum of serious bacterial infections.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05088421 A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers Phase 1 Interventional Bugworks Research Inc.